Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devrim Cabuk

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Molecular and Cellular Probes|May 1, 2022
The diagnostic importance of pathogenic variants and variant coexistence determined by NGS-based liquid biopsy approach in patients with lung adenocarcinomaNaci Cine, Emin Ali Sen, Gulhan Demir, et al.
Journal of Biotechnology|May 18, 2019
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testingHakan Savli, Nilüfer Sertdemir, Duygu Aydin, et al.
Anti-Cancer Drugs|March 31, 2025
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group studySelin Akturk Esen, Ismet Seven, Gonca Akdere Ates, et al.
Frontiers in Immunology|March 2, 2026
Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective studyMustafa Ersoy, Umut Kefeli, Devrim Cabuk, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|November 18, 2018
Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)Esin Oktay, Mustafa Levent, Hakan Gelincik, et al.
Journal of Clinical Medicine|January 28, 2026
Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung CancerAyse Nuransoy Cengiz, Oktay Bozkurt, Muhammet Cengiz, et al.
Expert Review of Anticancer Therapy|January 9, 2026
Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancerEmel Mutlu Ozkan, Ibrahim Karadağ, Elif Sahın, et al.
Scientific Reports|May 8, 2026
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patientsMuhammet Cengiz, Oktay Bozkurt, Ayse Nuransoy Cengiz, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Anti-Cancer Drugs|June 15, 2022
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group studyÖzlem Özdemir, Baha Zengel, Yaşar Yildiz, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Molecular and Cellular Probes|May 1, 2022
The diagnostic importance of pathogenic variants and variant coexistence determined by NGS-based liquid biopsy approach in patients with lung adenocarcinomaNaci Cine, Emin Ali Sen, Gulhan Demir, et al.
Journal of Biotechnology|May 18, 2019
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testingHakan Savli, Nilüfer Sertdemir, Duygu Aydin, et al.
Anti-Cancer Drugs|March 31, 2025
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group studySelin Akturk Esen, Ismet Seven, Gonca Akdere Ates, et al.
Frontiers in Immunology|March 2, 2026
Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective studyMustafa Ersoy, Umut Kefeli, Devrim Cabuk, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|November 18, 2018
Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)Esin Oktay, Mustafa Levent, Hakan Gelincik, et al.
Journal of Clinical Medicine|January 28, 2026
Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung CancerAyse Nuransoy Cengiz, Oktay Bozkurt, Muhammet Cengiz, et al.
Expert Review of Anticancer Therapy|January 9, 2026
Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancerEmel Mutlu Ozkan, Ibrahim Karadağ, Elif Sahın, et al.
Scientific Reports|May 8, 2026
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patientsMuhammet Cengiz, Oktay Bozkurt, Ayse Nuransoy Cengiz, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Anti-Cancer Drugs|June 15, 2022
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group studyÖzlem Özdemir, Baha Zengel, Yaşar Yildiz, et al.
Pageof 4